Bayer HealthCare Pharmaceuticals has been in trouble with the FDA regarding advertisements for its oral contraceptive Yaz. It was alleged that marketing for Yaz violated an earlier consent judgment in a case resulting from Bayer’s advertising for the drug Baycol. Based on the terms of a supplemental judgment involving 27 states, Bayer will submit its Yaz television advertisements to the FDA for approval, prior to airing the ads in the U.S. In 2008, the FDA warned Bayer that 2 of its Yaz ads were "misleading because they broaden the drug’s indication, overstate the efficacy of Yaz, and minimize serious risks associated with use of the drug." In addition to submitting the advertisements for FDA approval, Bayer will have to clearly state exactly what conditions and symptoms Yaz is approved to treat.
Comments are closed.